News & Updates

The patient was a 70-year-old female who presented with a large, fungating left breast mass in September 2022. Although first symptoms were noticed approximately a year earlier, the patient did not seek consultation sooner for fear of cancer diagnosis. Upon examination, the mass occupied the entire left breast. The patient also suffered from shortness of breath and left breast pain. These symptoms worsened, resulting in hospitalization. 

Precision medicine and tumour-agnostic approach are changing the landscape of non-small-cell lung cancer (NSCLC) and many other advanced solid tumours without satisfactory standard treatments. In an industry-sponsored meeting endorsed by the Hong Kong Society of Clinical Oncology, Professor Jürgen Wolf of the Center for Integrated Oncology, University of Cologne, Germany, lead investigator of an international phase II trial that led to the approval of capmatinib for advanced NSCLC harbouring MET exon 14 (METex14) skipping mutation, discussed the importance of panel molecular testing and targeted therapy in different solid tumours, focusing in particular on advanced NSCLC with actionable driver mutations, such as MET alterations.